Home
overview
Expert industry speakers include:
Dr Patrick May, Head, Neuroscience Discovery Research, Eli Lilly
Dr Guy Seabrook, Director, Cellular & Molecular Neuroscience, Merck
Dr Ivan Lieberburg, Chief Scientific & Medical Officer, Elan
Prof Ruggero Fariello, Chief Scientific Officer, Newron Pharmaceuticals
Prof Alan Kingsman, Chief Executive Officer, Oxford BioMedica
Dr Rudolf Urbanics, Deputy Director, Research & Development, Biorex
Dr Roman Urfer, Vice President, Drug Discovery & Development, AGY Therapeutics
Dr David Rubinsztein, Wellcome Trust Senior Fellow, University of Cambridge
Dr Christian Gilles, Director, Research & Development & Head, CNS Ageing Research, Forenap

Benefits of Attending
BRAIN IMAGING: Gain insight into imaging amyloid plaques for diagnosing Alzheimer’s disease
MOLECULAR GENETICS: Understand gene delivery to the nervous system for dopamine replacement therapy
THERAPEUTIC TARGETS: Discover JNK inhibitors as neuroprotectors against inflammatory destruction
COGNITIVE DECLINE: Assess the differing profiles and implications for therapy
NEW DRUGS ON TRIAL: Investigate unique new therapeutic agents and innovative model systems for treating neurodegenerative diseases

“Informative, Intensive, Interesting”
Rudolf Urbanics, Deputy Director, Research & Development, Biorex
Attendee, SMi’s Neurodegenerative Disorders Conference 2002

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr David Rubinsztein

Dr David Rubinsztein, Wellcome Trust Senior Fellow, University of Cambridge

9:10 INTRODUCTION TO PARKINSON’S DISEASE

Dr Michael Wess

Dr Michael Wess, Vice President, Scientific & Medical Affairs, Amarin Pharmaceuticals

  • Aetiology of the disease
  • Neuronal apoptosis and neurodegeneration
  • Markers of chronic CNS inflammation and immune activation in Parkinson’s disease
  • Influence of genetics in the pathophysiology and treatment of Parkinson’s disease
  • Should dopamine replacement yield constant or pulsatile dopamine levels; is levodopa toxic?
  • Controversies in treatment: MAO-B inhibition and COMT inhibition
  • 9:40 INTRODUCTION TO ALZHEIMER’S DISEASE AND AD ANIMAL MODELS

    Dr Rudolf Urbanics

    Dr Rudolf Urbanics, Deputy Director Research & Development, Biorex

  • Cellular and molecular neuropathology in Alzheimer's disease
  • Role of oxidative damage initiating chronic neurodegenerative diseases
  • Mitochondrial damage in AD
  • Introduction of chronic mitochondrial in vivo rat poisoning model
  • 10:20 TREATING ALZHEIMER’S DISEASE

    Dr Patrick May

    Dr Patrick May, Head, Neuroscience Discovery Research, Eli Lilly

  • Amyloid hypothesis of AD
  • Gamma-secretase inhibitors
  • Beta-secretase inhibitors
  • Active and passive immunization
  • Future therapeutics
  • 11:00 Morning Coffee

    11:20 THE NEW MOLECULAR GENETICS OF THE NERVOUS SYSTEM

    Professor Alan Kingsman

    Professor Alan Kingsman, Chief Executive Officer, Oxford BioMedica

  • The requirement for molecular genetic analysis
  • Gene delivery to the nervous system
  • Targets and models
  • ProSavin – genetic dopamine replacement therapy
  • Clinical development
  • Neuroprotective approaches for Parkinson’s disease
  • 12:00 CONNECTION WITH HUNTINGTON’S DISEASE

    Dr David Rubinsztein

    Dr David Rubinsztein, Wellcome Trust Senior Fellow, University of Cambridge

  • Genetics of Huntington’s disease
  • Role of aggregates in Huntington’s disease
  • How do cells manage aggregate-prone proteins?
  • Proteinopathies – polyglutamine expansion diseases
  • Proteinopathies – Parkinson’s disease
  • Proteinopathies – Alzheimer’s disease
  • 12:40 Networking Lunch

    13:40 CONNECTION WITH PRION DISORDERS

    Dr Celine Adessi

    Dr Celine Adessi, Scientist, CNS Research, Hoffman-La Roche

  • Prions: infectious proteins
  • Molecular mechanism of prion protein misfolding and aggregation
  • How do misfolded prions induce neurodegeneration? Is there a common pathway of brain damage?
  • Using prion replication principles to design novel therapies for neurodegenerative diseases
  • Using prion replication principles to design novel diagnostic procedures for neurodegenerative diseases
  • How common is the prion phenomenon of propagation of biological information by transmission of protein folding?
  • 14:20 DISCOVERY OF NOVEL TREATMENTS FOR NEURODEGENERATIVE DISORDERS

    Dr Roman Urfer

    Dr Roman Urfer, Vice President, Drug Discovery & Development, AGY Therapeutics

  • Target identification by gene expression profiling of disease models
  • Pathway building by interactor analysis
  • Target validation using RNAi technology in neurons
  • Compound identification by assay development and high-throughput screening
  • 15:00 IMAGING AMYLOID PLAQUES IN ALZHEIMER’S DISEASE

    Dr Henry Engler

    Dr Henry Engler, Medical Director, Uppsala Research Imaging Solutions

  • In vitro validation of PIB
  • The current human study
  • PIB uptake in healthy volunteers
  • PIB uptake in Alzheimer patients
  • PIB and FDG uptake
  • Tact plots for AD patients and healthy volunteers
  • 15:40 Afternoon Tea

    16:00 THE ROLE OF BIOMARKERS IN EARLY AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER’S DISEASE

    Dr Ann vanden Wyngaerd

    Dr Ann vanden Wyngaerd, Neurodegenerative Disease Program Manager, Innogenetics

  • Consensus guidelines on biomarkers
  • Major outcome of the literature
  • Application in clinical routine
  • Utility for pharmaceutical companies in drug selection and clinical trials
  • Future perspectives
  • 16:40 AD BIOMARKERS FOR EARLY DIAGNOSIS AND DRUG TREATMENT RESPONSE

    Dr Huw Davies

    Dr Huw Davies, Manager, European Biomarker Discovery Centre, Ciphergen Biosystems

  • Application of protein profiling and bioinformatics to find novel biomarkers
  • Validation of markers in patient cerebrospinal fluid samples
  • Sequence identification of discriminatory markers for mechanistic understanding
  • Antibody arrays for screening disease related proteins
  • 17:20 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Linda Surh

    Dr Linda Surh, Director, Disease Genetics, GlaxoSmithKline

    9:10 MODEL SYSTEMS FOR NEURODEGENERATIVE DISEASE

    Dr Stefaan Wera

    Dr Stefaan Wera, Chief Executive Officer, reMYND

  • Validation of lead compounds in APP transgenic mice
  • Alpha-synuclein-transducted mice and rats: novel and better Parkinson’s disease models
  • Budding yeast: a versatile model system
  • Processing of APP in yeast
  • Yeast as a screening tool for tauopathy lead discovery
  • 9:40 DIFFERING PROFILES OF COGNITIVE DECLINE IN VARIOUS NEURODEGENERATIVE DEMENTIAS

    Professor Keith Wesnes

    Professor Keith Wesnes, Chief Executive Officer, Cognitive Drug Research

  • Aspects of cognitive dysfunction, particularly attention, are under-recognised in all non-degenerative dementias
  • The profile of deficits to attention varies greatly between different dementias
  • Data to illustrate this in PD, PDD, DLB, AD, VaD & HC
  • Data and the differential response of various cognitive deficits to anti-cholinesterase inhibitors in AD, DLB & PDD
  • Implications for future therapies
  • 10:20 FUNCTIONAL SCREENING IN BRAIN RESEARCH

    Dr Cara Heers

    Dr Cara Heers, Manager, Business Development, KeyNeurotek

  • Introduction to stroke pathology
  • Common models for stroke research
  • TELOMICS ex vivo and in vivo technologies for functional screening and target identification/validation
  • Applications for TELOMICS technologies
  • 11:00 Morning Coffee

    11:20 ISSUES IN THE DEVELOPMENT OF DRUGS FOR NEURODEGENERATIVE DISEASES

    Dr Christian Gilles

    Dr Christian Gilles, Director, Research & Development & Head, CNS Ageing Research, Forenap

  • Safety assessment
  • Proof of concept
  • Human models
  • Biomarkers/surrogate markers
  • Can we avoid lengthy patients’ studies?
  • Placebo effect
  • 12:00 MEMANTINE: A NEW APPROACH TO ALZHEIMER’S DISEASE

    Dr Hans Moebius

    Dr Hans Moebius, Managing Director & Vice President, Global Research & Development & DRA, Merz Pharmaceuticals

  • Memantine basics
  • Mode of action
  • Phase III results
  • Long-term treatment
  • Combination therapy of memantine with donepezil
  • Future prospects
  • 12:40 Networking Lunch

    13:40 NEW DRUG CANDIDATE FOR PARKINSON’S

    Professor Ruggero Fariello

    Professor Ruggero Fariello, Chief Scientific Officer, Newron Pharmaceuticals

  • Safinamide strengthens the resistance of neurons
  • Mechanism of action
  • Phase II study result
  • Potential as a neuroprotectant
  • Use in combination therapies
  • 14:20 ANOTHER NEW DRUG CANDIDATE FOR PARKINSON’S DISEASE

    Dr Guy Seabrook

    Dr Guy Seabrook, Director, Cellular & Molecular Neuroscience, Merck

  • Coenzyme Q10
  • Improving the function of mitochondria
  • Potent antioxidant
  • Possible neuroprotection
  • Placebo-controlled, multicentre clinical trial results
  • FDA regulation
  • 15:00 HEPATIC PARASYMPATHETIC NEUROPATHY, A NEW PARADIGM IN INSULIN RESISTANCE IN DIABETES

    Professor Wayne Lautt

    Professor Wayne Lautt, President & Chief Scientific Officer, DiaMedica

  • Parasympathetic nerves
  • Insulin resistance
  • Acetylcholinesterase antagonists
  • Phosphodiesterase antagonists
  • Muscarinic agonists
  • Hepatic insulin sensitizing substance (HISS)
  • 15:40 Afternoon Tea

    16:00 JNKs AS THERAPEUTIC TARGETS

    Professor Thomas Herdegen

    Professor Thomas Herdegen, Head, Pharmacology Institute, University of Kiel

  • JNKs mediate neurodegeneration in animals in particular oxidative-mitochondrial stress and cytoskeletal disarrangements
  • JNKs accumulate in post-mortem brain of Alzheimer’s patients
  • JNKs mediate activation of inflammatory microglia
  • JNK inhibitors successfully protect against inflammatory destruction in humans and animals
  • Knockout and pharmacological inhibition of JNKs rescue otherwise dying neurons in the brain
  • Shift from physiological to pathological functions of JNKs underlies some broadness of therapeutic window
  • 16:40 IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE

    Dr Ivan Lieberburg

    Dr Ivan Lieberburg, Chief Scientific & Medical Officer, Elan

  • Background
  • Approaches
  • Clinical trial status
  • Where do we go from here?
  • 17:20 Chairman’s Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.